Ardelyx Inc (ARDX)

[Whalatane]

Diarrhea is the most common adverse event with starting ARDX's phosphorus lowering drug . However it should be noted that almost 40% of those on dialysis takes laxatives because many of the drugs etc they take cause constipation.
37% take stool softeners . These patients who are currently nowhere near goal on serum phosphorous levels will be the first to try ARDX's drug . To date no EU partner which leads me to speculate that this Co may be a buy out target for an EU based Co like CSL Vifor that already has a well established cardio- renal sales team.
JMO
Not investment advice
Kiwi